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P rimary malignant tumors of the pulmonary artery(PA) are rare. The diagnosis is either delayed or
established after death because symptoms are nonspe-
Objective: Pulmonary artery sarcomas are rare and usually fatal tumors. The
diagnosis is difficult and delayed in most cases. Newer imaging techniques
could allow early diagnosis in patients with symptoms of pulmonary vascu-
lar obstruction. Surgical resection improves clinical symptoms and offers the
only chance of cure. We report the case histories of 7 patients with primary
pulmonary artery sarcomas treated by surgical resection with or without
adjuvant therapy.
Methods: Seven patients (3 women and 4 men; mean age, 52.3 years; preop-
erative New York Heart Association functional class III/IV, n = 5/2) under-
went operations. Malignancy was preoperatively suspected in 5 patients, and
2 patients had a presumptive diagnosis of chronic pulmonary embolism.
Tumor resection with partial or total prosthetic replacement (n = 2), recon-
struction (n = 5), or both, of central parts of the pulmonary arteries was per-
formed in 6 patients. Thromboendarterectomy was necessary in 4 patients,
and pneumonectomy was necessary in 2 patients. Six patients received adju-
vant therapy.
Results: There was no perioperative mortality. All patients had a substantial
improvement in exercise tolerance and hemodynamics 3 months after their
operations. Four patients died 7, 9, 18, and 19 months after their operations
because of recurrent tumor or pulmonary metastases. Two patients are alive
21 and 35 months after primary surgical repair, with pulmonary metastases
detected by computed tomographic scans. One patient is alive 62 months
after resection without clinical or radiologic signs of tumor recurrence or
metastasis.
Conclusions: Early diagnosis of primary pulmonary artery sarcomas can be
improved by computed tomography and magnetic resonance scanning.
Radical surgical resection probably presents the only chance for cure. The
role of neoadjuvant or adjuvant treatment modalities has to be defined.
Pulmonary artery sarcoma need not necessarily be a fatal diagnosis. 
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cific and survival time is limited. With newer radiolog-
ic imaging techniques, earlier identification seems to be
feasible. Aggressive surgical treatment improves clini-
cal symptoms and offers the only chance for cure.
Since 1989, a multidisciplinary program for diagnosis
and treatment of pulmonary hypertension by throm-
boendarterectomy or lung transplantation has been
established at our institution.1,2 Therefore, a significant
number of patients with different causes of pulmonary
hypertension have been referred for further evaluation
and consequent surgical therapy. Between April 1989
and December 1998, 7 patients with primary sarcoma
of the PA underwent resection with or without
chemotherapy, radiotherapy, or both. We report these
cases, including clinical presentation, diagnosis, surgi-
cal management, and outcome.
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Patients and methods
From January 1988 to December 1998, 7 patients (3
women and 4 men; mean age, 52.3 years; age range, 31-61
years) were identified. Their symptoms were severe dyspnea
(New York Heart Association functional class III/IV, n = 5/2),
cough (n = 5), weight loss (n = 5), fatigue (n = 4), and chest
pain (n = 2), with an average duration of symptoms of 6
months (range, 1-16 months). Specific evaluation included
computed tomography (CT; n = 7), magnetic resonance imag-
ing (MRI; n = 3), pulmonary angiography (n = 5), and
echocardiography (n = 6). Malignancy was preoperatively
suspected in 5 patients on the basis of CT or MRI scanning
(Fig 1), and 2 patients had a presumptive diagnosis of sub-
acute or chronic pulmonary embolism.
In 6 patients (patients 1, 2, 3, 4, 6, and 7), the histologic
diagnosis of malignancy was established intraoperatively
with frozen sections, and the tumor was resected radically
with the aid of hypothermic cardiopulmonary bypass (n = 6).
The completeness of resection was determined by frozen sec-
tion diagnosis. Tumor resection with partial or total prosthet-
ic replacement (n = 2), reconstruction (n = 5), or both, of cen-
tral parts of the pulmonary arteries was performed in 6
patients. In these patients the tumor origin was clearly locat-
ed or macroscopically suspected at the pulmonary valve or in
the central part of the PA. The corresponding areas of the vas-
cular wall were widely resected, followed by partial or total
prosthetic replacement. Thromboendarterectomy for intralu-
minal peripheral tumor growth was necessary in 4 patients
(patients 2, 3, 6, and 7), and 2 (patients 3 and 6) patients
underwent additional pneumonectomy for histologically
proven peripheral tumor spread not safely accessible through
thromboendarterectomy techniques, despite periods of circu-
latory arrest. In 1 patient (patient 7), intraoperative frozen
sections revealed a tumor invasion of the aortic root, with
peripheral disease within the right PA segmental branches.
This patient underwent gross intraluminal tumor resection
and main PA reconstruction for palliative restoration of blood
flow. One patient (patient 5) underwent pulmonary throm-
boendarterectomy for suspected subacute pulmonary
embolism. Postoperatively, histologic examination of the
specimen removed revealed a leiomyosarcoma. This patient
was reoperated on after 7 months for recurrence of a central
PA tumor (Fig 2) and a large solitary pulmonary metastasis.
She underwent right ventricular outflow tract, pulmonary
valve, pulmonary trunk, and right PA resection and replace-
ment with polytetrafluoroethylene prostheses and a pul-
monary valve homograft combined with a left-sided pneu-
monectomy. Another patient (patient 6) was reoperated on
after 4 months for a solitary pulmonary metastasis by right
lower lobe wedge resection (Table I).
One patient (patient 2) did not receive adjuvant therapy, 1
patient (patient 1) received postoperative radiotherapy, 4
patients (patients 4, 5, 6, and 7) had adjuvant chemotherapy,
and 1 patient (patient 3) had combined chemotherapy and
radiotherapy.
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Fig 1. A, MRI scan (patient 7) shows central PA obstruction (arrow). B, Same scan with inhomogeneous enhance-
ment of contrast medium.
A B
Fig 2. MRI scan (patient 5) showing recurrent pulmonary sar-
coma (*) within the left hilum 7 months after pulmonary
thromboendarterectomy.
Results
Intraoperative frozen section diagnosis was achieved
in 6 patients. Three patients (patients 1, 2, and 4) had
negative resection margins, 2 patients (patients 3 and 6)
received pneumonectomy on the basis of positive mar-
gins, and 1 patient (patient 7) had tumor invasion of the
aortic root without possibility of further resection. Final
histologic and immunohistochemical examinations
showed a myogenous tumor growth pattern in 5 patients,
with positive smooth muscle differentiation (desmin) in
5 and smooth muscle actin in 4 patients, representing
leiomyosarcomas (Fig 3). The 2 other specimens
showed areas resembling malignant fibrous histiocy-
toma and were classified as intimal sarcomas. Results of
the immunohistochemical analysis are shown in Table II.
All patients survived the operation (reoperation), and
2 patients had bleeding complications after pneu-
monectomy. However, surgical reintervention for
bleeding was not necessary. Three months after the
operations, all patients were in New York Heart
Association functional class I (n = 4) or II (n = 3), with
a substantial improvement in exercise tolerance and
hemodynamics.
Four patients (patients 1, 2, 3, and 5) died at 7, 9, 18,
and 19 months after primary operations of recurrent
tumor (patients 1, 3, and 5) and multiple pulmonary
metastases (patients 1 and 2). Three of them (patients 1,
3, and 5) had radiotherapy, chemotherapy, or both, as an
adjuvant treatment. Two patients (patients 6 and 7) are
alive 35 and 21 months, respectively, after primary resec-
tion and 31 months after reoperation (patient 6). Despite
adjuvant chemotherapy, pulmonary metastases (patients
6 and 7) occurred in 2 patients, with no option for further
surgical intervention. One patient (patient 4) is alive 62
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Table I. Patient characteristics and therapeutic procedures
Patient No. Sex Age (y) Surgical procedure Reoperation Adjuvant therapy Survival
1 M 56 Tumor resection, PA reconstruction Radiotherapy Died, 18 mo
2 F 43 Tumor resection, thromboendarterectomy, None Died, 9 mo 
PA replacement
3 M 60 Tumor resection, thromboendarterectomy, Radiotherapy and Died, 7 mo
right pneumonectomy, PA reconstruction chemotherapy
4 M 31 Tumor and right ventricular outflow Chemotherapy Alive, 62 mo,
tract resection and reconstruction without disease
5 F 49 Thromboendarterectomy 7 mo Chemotherapy Died, 19 mo
6 M 61 Tumor resection, thromboendarterectomy, 4 mo Chemotherapy Alive, 35 mo, with 
left pneumonectomy, PA replacement pulmonary metastases
7 M 60 Gross tumor resection, thromboendarterectomy Chemotherapy Alive, 21 mo, with
pulmonary metastases
Fig 3. Histology (patient 4): leiomyosarcoma. (Hematoxylin and eosin; original magnification 250×.)
months after the operation, without clinical or radiologic
(including MRI) signs of tumor recurrence or metastasis
(Table I). Overall median survival was 19 months.
Discussion
Primary tumors of the PA are rare and usually repre-
sent sarcomatous neoplasms arising within the intima
of the pulmonary trunk3 or the bulbus cordis.4 The
tumor growth in the central PA with additional apposi-
tional thrombosis is leading to a progressive obstruc-
tion of right ventricular blood flow into the pulmonary
circulation.5 Emboli to the peripheral pulmonary vas-
culature may increase right ventricular afterload,
resulting in progressive right heart failure. Without sur-
gical intervention, a mean survival time of 1.5 months
after diagnosis has been calculated on the basis of 93
cases reported in the literature.6
Dyspnea, chest pain, cough, hemoptysis, and syn-
cope are characteristic symptoms of significant pul-
monary vascular obstruction. However, in our experi-
ence with more than 200 thromboendarterectomy
operations for chronic pulmonary embolism since
1989,1,2 the diagnosis of chronic thromboembolic pul-
monary hypertension is often missed or delayed for
months or years. It can be speculated that in the major-
ity of patients with fast-growing PA tumors and pro-
gressive cardiopulmonary dysfunction, the diagnosis
will not be established before death. Therefore, 60% of
the cases reported in the literature have been identified
at autopsy.6
All our patients had severe and progressive dyspnea
for 1 to 16 months before referral to our institution.
Multiple clinical and radiologic investigations, includ-
ing CT, had been performed in all cases. Only in 2
patients was malignancy suspected because of a medi-
astinal mass detected with CT and an obstructive mass
originating from the pulmonary valve detected with
transesophageal echocardiography, respectively. These
2 patients were referred for tumor resection. Five
patients were referred for surgical therapy of recurrent
or chronic pulmonary embolism and underwent a rou-
tine preoperative evaluation, including pulmonary
angiography, CT, and MRI (n = 3). In 3 of the patients,
a malignant intraluminal PA tumor was suspected on
the basis of heterogeneous contrast medium enhance-
ment in CT or MRI. The preoperative diagnosis in the
remaining 2 patients was chronic thromboembolic pul-
monary hypertension. In conclusion, 4 of 5 intralumi-
nal PA obstructions and 1 mediastinal mass originating
from the main PA were preoperatively suggested to be
malignant. Compared with the literature reports, this is
a rather favorable rate of adequate preoperative diagno-
sis that can be explained by a significant experience
with patients with chronic pulmonary embolism and
the corresponding CT and MRI findings at our institu-
tion.7,8 Furthermore, it is likely that chest physicians
with a single case experience of PA sarcoma will
always include this differential diagnosis when more
patients are referred for chronic thromboembolic dis-
ease, as is the case at our institution.
Several reports suggest that CT and MRI may be the
most useful modalities for differentiation between
tumor and thrombotic material.7-10 After application of
gadolinium-diethylene-triamine-pentaacetic acid, the
heterogenous enhancement demonstrated by MRI is
characteristic of a vascularized tumor. In rare cases a
pedunculated mass arising from the right ventricular
outflow tract, pulmonary valve, or pulmonary trunk
demonstrated by echocardiography or MRI may be
pathognomonic for sarcoma, as in our patient 4, in
whom the tumor was detected with echocardiography
at an early stage. Therefore, we consider CT and MRI
scanning, combined with transthoracic echocardiogra-
phy, as sufficient measures for differentiation between
tumor and thrombus. Furthermore, a significant experi-
ence with diagnosis of chronic thromboembolic pul-
monary hypertension seems to be necessary in this rare
entity. Preoperative pathologic diagnosis for a better
planning of the surgical approach can be achieved by
using endovascular catheter biopsy.11 However,
because appositional thrombotic material covering the
tumor is frequent, the sensitivity of the biopsy proce-




Patient No. Classification Vimentin Desmin Smooth muscle actin Cytokeratin Factor VIII
1 Leiomyosarcoma Positive Positive Positive Negative Negative
2 Leiomyosarcoma Positive Negative Positive Negative Negative
3 Intimal sarcoma Positive Negative Negative Negative Negative
4 Regressive leiomyosarcoma Positive Positive Positive Negative Negative
5 Leiomyosarcoma Positive Positive Negative Negative Negative
6 Intimal sarcoma plus malignant osteoid Positive Negative Negative Negative Negative
7 Leiomyosarcoma Positive Positive Positive Negative Negative
dure has to be evaluated. It is also unlikely that pul-
monary angiography is a reliable method for differenti-
ation between thrombus and tumor, whereas pressure
gradients between the right ventricular outflow tract
and the PA trunk may be helpful in establishing the
diagnosis because significant gradients in the central
PA are unlikely in thromboembolic disease.
Although fewer than 130 cases have been reported in
the literature, a wide variety of the histopathologic pat-
tern of the tumors could be found. Most sarcomas of
the PA are luminal sarcomas, which are usually poorly
differentiated or undifferentiated and have been called
intimal sarcomas. Three of 13 luminal PA sarcomas
examined by Burke and Virmani12 did not fit under the
classification of intimal sarcomas and were identified
as a luminal angiosarcoma, an undifferentiated mural
sarcoma, and a mural leimyosarcoma. A myxoid back-
ground was present in 8 intimal sarcomas, and 3 dis-
played malignant osteoid. In our series we examined 5
leiomyosarcomas and 2 intimal sarcomas. One intimal
sarcoma was classified as malignant mesenchymoma
of intimal origin because it showed fibroblastic and
osteosarcomatous differentiation. However, Burke and
Virmani pointed out that PA sarcomas frequently
demonstrate osteosarcomatous or chondrosarcomatous
differentiation and should not be classified as mes-
enchymoma, unless there are areas of liposarcoma,
myosarcoma, or angiosarcoma as well. Other reports
mentioned that approximately 50% of PA sarcomas are
of fibroblastic or myofibroblastic origin, whereas 20%
are leiomyosarcomas. Another 30% of the cases were
subclassified.13 Although previous immunohistochemi-
cal studies have aided in the subclassification of great
vessel sarcomas,14 it is not possible to date to definite-
ly determine the cell of tumor origin by immunohisto-
chemical findings.
In patients with advanced PA sarcoma and significant
vascular obstruction, surgical treatment offers adequate
palliation and increases length of survival.6,15-17
Aggressive surgical resection may even be curative in
patients with localized lesions and early diagnosis.
Depending on tumor localization, distal extension, and
the presence of pulmonary metastases, surgical therapy
includes tumor and PA resection and reconstruction,
endarterectomy techniques, and pneumonectomy.
Because tumor lesions are usually originating from the
central parts of the PA or the pulmonary valve, the use
of cardiopulmonary bypass seems to be essential in all
cases. In 6 of our 7 patients, tumor and PA resection
was performed with additional endarterectomy in 4 and
pneumonectomy in 2 patients. Because 1 of these
patients has survived for more than 5 years without
signs of tumor recurrence, we do prefer aggressive
resection rather than endarterectomy alone whenever
possible. Hypothermic circulatory arrest was used in 3
patients. One patient underwent a routine endarterecto-
my operation with circulatory arrest periods, and post-
operative histology revealed the tumor growth within
the thrombotic material. In 2 patients circulatory arrest
was instituted after inadequate peripheral endarterecto-
my because of poor visibility under low-flow condi-
tions. Because the frozen sections of the endarterecto-
my specimen in these 2 patients revealed unilateral
peripheral positive margins, both patients received
additional pneumonectomy, and 1 patient is alive 35
months after the operation, despite the presence of con-
tralateral pulmonary metastases. Although the role of
pneumonectomy in this context remains to be defined,
it is a therapeutic option in combination with central
PA resection when frozen sections reveal unilateral
peripheral tumor spread.
Because median survival of these patients without
surgical intervention is limited to approximately 1.5
months6 and quality of life is poor because of progres-
sive right heart dysfunction,5 surgical treatment should
be attempted in any case, even if cure seems unlikely.
In this series there was no operative mortality and a sig-
nificant improvement in exercise tolerance, and quality
of life was achieved in all patients for months or years
after operations. Although tumor recurrence (n = 4),
pulmonary metastases (n = 4), or both, occurred in 6 of
our 7 patients, the median length of survival could be
increased to 19 months. On the basis of previous
reports of 27 patients with surgical resection in the lit-
erature, Krüger and colleagues6 calculated a median
survival of 10 months, with an early mortality of 22%.
Although sufficient data on adjuvant treatment are not
available in the literature, neoadjuvant or adjuvant
radiotherapy, chemotherapy, or both, in addition to
resection, may play a role in an interdisciplinary
approach and might increase the length of survival.5,18
Five of our 7 patients received postoperative
chemotherapy, and 2 are alive 21 and 35 months,
respectively, after their operations with partial remis-
sions of pulmonary metastases or recurrent tumor after
polychemotherapy. The only long-term survivor with-
out tumor recurrence also had postoperative
chemotherapy.
Primary PA sarcomas are extremely uncommon
tumors. The diagnosis is difficult and usually delayed.
Early diagnosis in patients with characteristic symp-
toms of pulmonary vascular obstruction can be
improved by CT and MRI scanning. Early radical sur-
gical resection with cardiopulmonary bypass probably
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presents the only opportunity for a potential cure. In
extensive bilateral disease surgical therapy offers sig-
nificant palliation and increases length of survival. The
role of adjuvant or neoadjuvant treatment strategies
will have to be defined. PA sarcoma need not necessar-
ily be a fatal diagnosis.
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